The right drug targets for the right patient – Using biomarkers to solve challenges in drug development

Available on demand

Protein biomarkers provide a dynamic and powerful approach to identify and understand novel drug targets in early in drug development. The pharmaceutical industry utilizes biomarkers to help uncover disease progression markers, responder signatures, diagnostic biomarkers, and potential new indications. Join us for this virtual roundtable discussion where leading experts will:

• Share their opinions on how biomarkers can help drive early clinical phase trials
• Discuss their work with biomarkers at present
• Explore the history of protein biomarkers within their organization
• Predict how the field will evolve to meet future challenges

As well as advancements, panelists will also highlight potential challenges and issues that the pharmaceutical industry encounter during the use of protein markers in discovery and what needs to improve.

Panelists include:

• Dr. Jürgen Braunger of Boehringer Ingelheim Pharma
• Dr. Timothy Radstake of AbbVie
• Dr. Christopher D. Whelan of Biogen

Key learning objectives

From this webinar, you will gain an understanding of the challenges and solutions behind the use of protein biomarkers in drug discovery, and appreciate the use of protein biomarker solutions for patient stratification by disease severity.

Who should attend?

Pharma and academics working in drug discovery and drug development

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.